Navigation Links
Expansion and Relocation to New, State-Of-The-Art Facilities Marks Milestone in Effort to Roll Out New Tool for Cancer Diagnosis
Date:5/12/2008

or in RedPath from the beginning and we are pleased to lead in this latest investment round," said Brian Murphy, Chairman of RedPath's Board of Directors and Partner in NewSpring Capital, which invests in biopharmaceutical, medical devises and healthcare services companies. "RedPath has seen significant returns on its groundbreaking work and is well-positioned to help change the way cancers are diagnosed. We are very pleased to be a part of it."

The company's PathFinderTG(R) represents a significant advance in minimally intrusive and early diagnosis of cancer. RedPath provides molecular-based testing in the majority of the country's top cancer centers, enabling oncologists, pathologists and their patients to gain meaningful results from much smaller tissue samples as they work to diagnose tumors and abnormal growths.

"A primary advantage of PathFinderTG(R) is that it makes fine needle biopsies so much more reliable that physicians and health care providers may not require more extensive and costly surgical biopsy procedures for the diagnosis and treatment of cancer," said Mary Del Brady. "Even with the small tissue samples gathered through the use of PathFinderTG(R), we have found it to be an extremely accurate and effective tool in the diagnosis of disease."

As a result of the increasing use and popularity of PathFinderTG(R) in the healthcare community, RedPath has quadrupled its sales force and expects sales to triple over the next 12 months.

About RedPath Integrated Pathology Inc.

RedPath Integrated Pathology, Inc., founded in 2004, is a national genomics-based diagnostics company that provides complex cancer diagnostic testing for pathologists, oncologists and clinicians. Its patented molecular-based analysis, PathFinderTG(R), integrates with routine pathology review of fixed slides, cytology and fluid specimens to render an earlier and more definitive diagnosis, improving patient outcomes and reducing healthcare costs. '/>"/>

SOURCE RedPath Integrated Pathology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
3. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
4. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
5. Genzyme Begins Major Expansion of Boston Manufacturing Facility
6. ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office
7. AQUISS Continues Expansion Into New Territory
8. Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
9. SAFC Hitech(TM) Plans Further Expansion Into Asia
10. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
11. Mathew to Lead PPD Drug Development Operations and Expansion in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Die SARAH-Studie ... Assistance Publique - Hôpitaux de ... französische, gemeinschaftliche, randomisierte Kontrollstudie für die mehr ... werden Patienten mit fortgeschrittenem hepatozellulärem Karzinom (HCC), ... behandelt wurden. Die Ergebnisse werden für Ende ...
(Date:3/5/2015)... March 5, 2015   HX360 today announced ... the HX360 Innovation Challenge competition. These companies, ... to be chosen as one of four finalists to ... health system executives and venture capitalists during the Innovation ... takes place at the 2015 HIMSS Annual Conference & ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 BioPlus Specialty ... the position of Vice President of Managed Care. In ... relationships for one of the nation’s leading specialty pharmacies. ... than 15 years of specialty pharmacy and biotech experience ... with Raptor Pharmaceuticals, Vertex Pharmaceuticals, and Pfizer. Prior to ...
(Date:3/5/2015)... and TORONTO , March 5, 2015 ... clinical-stage company developing new therapeutics and molecular diagnostics that ... William G. Rice , Ph.D., Chairman, President and ... Annual ROTH Conference on Tuesday, March 10 th ... Laguna Niguel, CA. Dr. Rice ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3
... 2011 Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ... systems, announced today that its work entitled "Evaluation of ... in Healthy Volunteers" will be presented at the Eleventh ... held in San Francisco, California. "The selection ...
... N.J., Oct. 25, 2011 Quest Diagnostics Incorporated (NYSE: ... has begun the process of identifying a successor to Surya ... Board of Directors has formed a search committee, engaged a ... internal candidates. Dr. Mohapatra has agreed to ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in ... update on operations and disclosed the outcome of a ... by management and AMT,s Board of Directors that enables ... therapy development. The CHMP,s recent opinion, while not approving ...
Cached Biology Technology:Oramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA) 2Quest Diagnostics Initiates CEO Succession Process 2Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 2Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 3Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 4
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, North Carolina , ... in sein 35. Jahr als spezialisiertes Logistikunternehmen ... seine Position als einzige klinische Logistikfirma (Clinical ... soll. Die Kernbotschaft der neuen Kampagne lautet ... Protokollen und Lieferungen. Foto: ...
(Date:2/5/2015)... 2015 New Market Research Reports ... Forecasts To 2020 has Been Added to GrandViewReseach.com Report ... expected to reach USD 5.10 billion by 2020, according ... IR cameras help identify the site of tissue damage ... surging demand in medical imaging applications. They have been ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... trigger warning signals in our cells. As a result, genes ... to the external danger and to protect the organism. In ... corresponding DNA segment, the gene, needs to be expressed and ... exists as a long string that is coiled and bound ...
... Elsevier, a world-leading provider of scientific, technical and ... entered into an agreement with the American Association for ... of Geriatric Psychiatry (AJGP) beginning in January 2013. ... this relationship with Elsevier," commented Chris M. deVries, Chief ...
... Although the two disorders may seem dissimilar, epilepsy and ... to have schizophrenia, and a family history of epilepsy ... known whether the converse is true, i.e., whether a ... epilepsy. Multiple studies using varied investigative techniques ...
Cached Biology News:A small cut with a big impact 2Elsevier selected as new publisher of the American Journal of Geriatric Psychiatry 2Evidence of familial vulnerability for epilepsy and psychosis 2
Topoisomerase I...
... I from vaccinia virus is a type ... and negative superhelical turns (also called right- ... The product of the reaction is a ... or negative superhelical turns. DNA Topoisomerase I ...
...
... Topoisomerase I from vaccinia virus is a ... positive and negative superhelical turns (also called ... DNA. The product of the reaction is ... positive or negative superhelical turns. DNA Topoisomerase ...
Biology Products: